Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
2.53
Dollar change
-0.06
Percentage change
-2.32
%
IndexRUT P/E- EPS (ttm)-14.84 Insider Own4.08% Shs Outstand52.20M Perf Week2.43%
Market Cap132.07M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float50.07M Perf Month-20.94%
Income-757.20M PEG- EPS next Q-0.83 Inst Own78.65% Short Float9.81% Perf Quarter5.42%
Sales1.05B P/S0.13 EPS this Y67.90% Inst Trans-1.90% Short Ratio1.59 Perf Half Y-23.33%
Book/sh12.44 P/B0.20 EPS next Y- ROA-30.28% Short Interest4.91M Perf Year-71.57%
Cash/sh2.14 P/C1.18 EPS next 5Y- ROE-74.34% 52W Range1.42 - 13.67 Perf YTD5.42%
Dividend Est.- P/FCF- EPS past 5Y- ROI-68.24% 52W High-81.49% Beta1.20
Dividend TTM- Quick Ratio0.54 Sales past 5Y10.59% Gross Margin27.46% 52W Low78.17% ATR (14)0.27
Dividend Ex-Date- Current Ratio1.04 EPS Y/Y TTM-231.09% Oper. Margin-17.05% RSI (14)50.65 Volatility7.61% 10.29%
Employees1600 Debt/Eq1.35 Sales Y/Y TTM-6.32% Profit Margin-72.11% Recom1.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq0.71 EPS Q/Q45.91% Payout- Rel Volume0.35 Prev Close2.59
Sales Surprise-5.73% EPS Surprise-305.48% Sales Q/Q-16.36% EarningsMar 06 AMC Avg Volume3.09M Price2.53
SMA20-6.26% SMA5012.07% SMA200-32.67% Trades Volume1,088,975 Change-2.32%
Date Action Analyst Rating Change Price Target Change
Mar-07-24Upgrade The Benchmark Company Hold → Buy $5
Nov-20-23Resumed JP Morgan Underweight
Aug-29-23Downgrade The Benchmark Company Buy → Hold
Apr-10-23Upgrade The Benchmark Company Hold → Buy $22
Mar-17-23Downgrade JP Morgan Neutral → Underweight $23 → $9
Nov-10-22Downgrade The Benchmark Company Buy → Hold
Apr-29-22Downgrade Cantor Fitzgerald Overweight → Neutral
Jan-20-22Upgrade The Benchmark Company Hold → Buy $77
Nov-08-21Downgrade The Benchmark Company Buy → Hold
May-05-21Downgrade Argus Buy → Hold
Today 08:15AM
Mar-25-24 08:05AM
Mar-07-24 01:58PM
12:34PM
10:33AM
07:35AM Loading…
07:35AM
Mar-06-24 11:30PM
09:53PM
05:55PM
05:20PM
04:31PM
Feb-29-24 07:00AM
Feb-21-24 03:24PM
07:35AM
07:06AM
07:00AM Loading…
07:00AM
Jan-17-24 11:55AM
Jan-12-24 02:20PM
Jan-11-24 08:00AM
Jan-09-24 07:30AM
Dec-12-23 06:53AM
Dec-11-23 10:05AM
09:03AM
Nov-29-23 11:56AM
Nov-28-23 06:59AM
Nov-24-23 07:30AM
Nov-09-23 01:19PM
Nov-08-23 11:00PM
05:38PM
Oct-30-23 04:45PM
06:30AM Loading…
Oct-19-23 06:30AM
Oct-16-23 07:00AM
Oct-02-23 07:00AM
Sep-07-23 11:30AM
Aug-30-23 05:59AM
Aug-29-23 09:37AM
Aug-25-23 11:36AM
Aug-23-23 12:33PM
Aug-22-23 11:42AM
Aug-21-23 06:00PM
Aug-17-23 09:57AM
09:35AM
Aug-16-23 09:35AM
Aug-09-23 09:26AM
08:29AM
12:30AM
Aug-08-23 07:40PM
06:29PM
04:31PM
08:23AM
07:50AM
07:44AM
07:15AM
Aug-07-23 11:32AM
Aug-04-23 09:21AM
Aug-01-23 12:06PM
Jul-31-23 04:05PM
Jul-25-23 06:30AM
Jul-20-23 06:31PM
06:15PM
06:03PM
Jun-27-23 05:30PM
08:02AM
07:55AM
Jun-26-23 05:30AM
Jun-21-23 08:00PM
11:30AM
Jun-09-23 08:20AM
Jun-08-23 11:30AM
Jun-07-23 08:20AM
Jun-05-23 09:39AM
May-17-23 06:21AM
May-15-23 06:27PM
07:58AM
May-11-23 06:30AM
May-10-23 10:47AM
08:53AM
07:48AM
03:00AM
May-09-23 06:15PM
04:05PM
May-08-23 09:29AM
May-02-23 10:01AM
Apr-26-23 08:00PM
Apr-24-23 02:09AM
Apr-20-23 11:41AM
Apr-19-23 04:05PM
09:00AM
Apr-10-23 01:00PM
Mar-30-23 11:56AM
07:44AM
Mar-29-23 03:50PM
12:37PM
11:30AM
11:01AM
09:48AM
09:26AM
09:02AM
08:52AM
08:42AM
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zoon Kathryn CDirectorJun 02 '23Sale8.351,83015,28049,971Jul 24 08:28 AM
Zoon Kathryn CDirectorMay 25 '23Sale8.381,70014,24651,801Jul 24 08:28 AM
Last Close
Mar 28 04:00PM ET
4.69
Dollar change
+0.63
Percentage change
15.52
%
APVO Aptevo Therapeutics Inc weekly Stock Chart
Index- P/E- EPS (ttm)-72.07 Insider Own0.80% Shs Outstand0.53M Perf Week4.69%
Market Cap2.49M Forward P/E- EPS next Y-10.50 Insider Trans0.00% Shs Float0.53M Perf Month-31.54%
Income-17.41M PEG- EPS next Q-11.59 Inst Own8.30% Short Float5.44% Perf Quarter-43.45%
Sales0.00M P/S- EPS this Y-1966.44% Inst Trans- Short Ratio0.30 Perf Half Y-66.32%
Book/sh27.62 P/B0.17 EPS next Y66.67% ROA-63.16% Short Interest0.03M Perf Year-94.36%
Cash/sh31.89 P/C0.15 EPS next 5Y- ROE-123.54% 52W Range3.81 - 92.62 Perf YTD-41.11%
Dividend Est.- P/FCF- EPS past 5Y46.80% ROI-98.83% 52W High-94.94% Beta4.87
Dividend TTM- Quick Ratio2.64 Sales past 5Y-3.68% Gross Margin71.07% 52W Low23.10% ATR (14)0.80
Dividend Ex-Date- Current Ratio2.64 EPS Y/Y TTM-191.12% Oper. Margin0.00% RSI (14)43.75 Volatility12.74% 18.83%
Employees40 Debt/Eq0.44 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price10.50
Option/ShortNo / No LT Debt/Eq0.44 EPS Q/Q57.76% Payout0.00% Rel Volume3.07 Prev Close4.06
Sales Surprise- EPS Surprise39.75% Sales Q/Q- EarningsMar 06 BMO Avg Volume96.35K Price4.69
SMA20-10.64% SMA50-23.34% SMA200-75.98% Trades Volume295,411 Change15.52%
Date Action Analyst Rating Change Price Target Change
Nov-05-18Initiated Ladenburg Thalmann Buy
Oct-05-17Resumed Piper Jaffray Overweight $6
Mar-18-24 06:00AM
Mar-07-24 08:55AM
Mar-05-24 01:51PM
08:05AM
Mar-04-24 09:00AM
08:05AM Loading…
Nov-14-23 08:05AM
Nov-01-23 07:45AM
Aug-10-23 08:05AM
Aug-06-23 07:14AM
Aug-04-23 06:40PM
Aug-01-23 10:15PM
Jul-30-23 02:17PM
Jul-18-23 08:05AM
May-11-23 08:05AM
Apr-01-23 08:51AM
07:45AM Loading…
Mar-30-23 07:45AM
07:30AM
Mar-29-23 10:13AM
Mar-03-23 06:57PM
Feb-13-23 08:05AM
Jan-09-23 08:05AM
Dec-12-22 09:54AM
07:35AM
Nov-10-22 08:05AM
Nov-09-22 08:05AM
Nov-03-22 09:06AM
Sep-19-22 08:45AM
Aug-11-22 08:05AM
Jun-09-22 08:05AM
May-12-22 08:05AM
08:05AM Loading…
Apr-12-22 08:05AM
Mar-29-22 08:05AM
Mar-24-22 08:05AM
Feb-09-22 08:05AM
Jan-21-22 08:05AM
Dec-15-21 08:05AM
Dec-10-21 05:38PM
Nov-23-21 08:05AM
07:59AM
Nov-15-21 08:05AM
Nov-12-21 08:05AM
Nov-11-21 04:45PM
08:30AM
Nov-02-21 09:00AM
Oct-27-21 08:05AM
Oct-26-21 08:05AM
Sep-28-21 08:05AM
Aug-17-21 08:05AM
Aug-12-21 08:05AM
Jul-16-21 08:05AM
Jun-29-21 08:05AM
May-27-21 09:00AM
May-26-21 09:32AM
09:00AM
May-17-21 06:00AM
May-11-21 09:00AM
Apr-09-21 09:00AM
Mar-31-21 08:00AM
Feb-09-21 07:30PM
Jan-11-21 08:00AM
Jan-06-21 12:00PM
Dec-19-20 01:45PM
Dec-02-20 08:00AM
Nov-20-20 07:37AM
Nov-19-20 04:15PM
Nov-16-20 08:00AM
Nov-10-20 08:40AM
Nov-09-20 09:00AM
06:00AM
Nov-08-20 11:15PM
Nov-03-20 09:00AM
Sep-01-20 09:00AM
Aug-14-20 09:00AM
Aug-06-20 09:00AM
Jul-21-20 09:00AM
Jun-30-20 12:00PM
11:30AM
Jun-29-20 09:00AM
Jun-25-20 09:00AM
Jun-10-20 09:00AM
May-13-20 09:00AM
Apr-14-20 09:00AM
Mar-25-20 09:00AM
Mar-16-20 09:00AM
Feb-28-20 09:05AM
08:59AM
Jan-30-20 09:00AM
Jan-13-20 08:00AM
Dec-19-19 03:50PM
Dec-06-19 09:00AM
Nov-12-19 09:00AM
Nov-08-19 09:00AM
Nov-07-19 09:00AM
Oct-04-19 07:32AM
Oct-03-19 04:02PM
Sep-19-19 09:00AM
Aug-09-19 09:00AM
Aug-07-19 09:02AM
Jul-25-19 04:32PM
Jun-25-19 09:00AM
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.